Screener
Castle Biosciences CSTL Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| ASSETS | March 31, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Accounts payable | $15,038 | $18,711 |
| Accrued compensation | 19,111 | 38,287 |
| Contingent consideration | 1,000 | 1,000 |
| Operating lease liabilities | 1,254 | 1,325 |
| Current portion of long-term debt | 1,667 | 417 |
| Other accrued and current liabilities | 10,691 | 8,937 |
| Total current liabilities | 48,761 | 68,677 |
| Long-term debt | 8,399 | 9,640 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's operating lease liabilities (current)?
- Castle Biosciences (CSTL) reported operating lease liabilities (current) of $1.25M in Q1 2026.
- How has Castle Biosciences's operating lease liabilities (current) changed year-over-year?
- Castle Biosciences's operating lease liabilities (current) decreased by 12.6% year-over-year, from $1.44M to $1.25M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about Castle Biosciences's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude